The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
Active, not recruiting · NCT02485015 · Registry updated 2016-02-19Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 | 2016-02-19 | NCT02485015 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The First People's Hospital of Changzhou | 35 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||